Predicting performance of the HAS-BLED and ORBIT bleeding risk scores in patients with atrial fibrillation treated with Rivaroxaban: Observations from the prospective EMIR Registry
María Asunción Esteve‐Pastor(Centro de Investigación Biomédica en Red), Francisco Marı́n(Instituto Murciano de Investigación Biosanitaria), José Miguel Rivera‐Caravaca, Fernando Arribas(Hospital Universitario 12 De Octubre), José Manuel Vázquez‐Rodríguez(Complexo Hospitalario Universitario A Coruña), Gregory Y.H. Lip(Medical University of Białystok), Juan Cosı́n-Sales(Hospital Arnau de Vilanova), Marcelo Sanmartı́n(Universidad de Alcalá), Alejandro Pérez Cabeza(Centro de Investigación en Red en Enfermedades Cardiovasculares), Román Freixa‐Pamias(Hospital de Sant Joan Despí Moisès Broggi), Manuel Anguita Sánchez(Mayo Clinic in Florida), Vanessa Roldán(Hospital Universitario Virgen de la Arrixaca), Vivencio Barrios(Apple (Israel)), Esther Recalde(Hospital de Basurto), Jaime Masjuán(Universidad de Alcalá)
Cited by 16
Related Papers
2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS
|European Heart Journal|2017|3k
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up
|Journal of the American College of Cardiology|2020|2.9k
ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012
|European Journal of Heart Failure|2012|2.6k
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
|European Heart Journal|2016|2.5k
2016 ESC Position Paper on Cancer Treatments and Cardiovascular Toxicity Developed Under the Auspices of the ESC Committee for Practice Guidelines
|European Journal of Heart Failure|2016|1.8k